Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 8.70 GBp
Change Today -0.26 / -2.90%
Volume 3.3M
OXB On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 11:35 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

oxford biomedica plc (OXB) Snapshot

Open
8.76 GBp
Previous Close
8.96 GBp
Day High
8.93 GBp
Day Low
8.60 GBp
52 Week High
03/20/15 - 13.25 GBp
52 Week Low
08/13/14 - 2.85 GBp
Market Cap
223.8M
Average Volume 10 Days
2.4M
EPS TTM
-0.0047 GBp
Shares Outstanding
2.6B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OXFORD BIOMEDICA PLC (OXB)

Related News

No related news articles were found.

oxford biomedica plc (OXB) Related Businessweek News

No Related Businessweek News Found

oxford biomedica plc (OXB) Details

Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing RetinoStat that has completed Phase I trial for ‘wet’ age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease and OXB-102 that is in Phase I/II trials preparation for the treatment of Parkinson's disease; and MoNuDin, which is in pre-clinical stage for the treatment of motor neuron disease. In addition, the company is developing TroVax that is in Phase II trial for colorectal cancer, ovarian cancer, and mesothelioma; Anti-5T4 antibody, which is in Phase I trial for the treatment of cancer; and CAR-T 5T4, a combination of LentiVector and 5T4 platform. It has collaborations with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb, and Immune Design Corp. Oxford BioMedica plc was founded in 1995 and is based in Oxford, the United Kingdom.

134 Employees
Last Reported Date: 04/2/15
Founded in 1995

oxford biomedica plc (OXB) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 641.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 408.0K GBP
Chief Business Officer and Executive Director
Total Annual Compensation: 355.0K GBP
Chief Development Officer, Executive Director...
Total Annual Compensation: 140.0K GBP
Compensation as of Fiscal Year 2014.

oxford biomedica plc (OXB) Key Developments

Oxford BioMedica PLC Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 04:00 PM

Oxford BioMedica PLC Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 04:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: John Dawson, Chief Executive Officer and Executive Director.

Oxford BioMedica Provides Capital Expenditure Guidance for the Year 2015/2016

Oxford BioMedica provided capital expenditure guidance for the year 2015/2016. For the year, the company expected capital expenditure to be in the range of £20 million.

Oxford Biomedica plc Appoints Daniel Soland as Non-Executive Director

Oxford BioMedica plc announced the appointment of Daniel Soland as a Non-Executive Director of the Group. Mr. Soland was previously Senior Vice President and Chief Operating Officer of ViroPharma from 2008 until its acquisition by Shire in 2014. Mr. Soland's appointment will commence with immediate effect.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXB:LN 8.70 GBp -0.26

OXB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €13.55 EUR +0.05
Impax Laboratories Inc $48.47 USD +0.18
Pharming Group NV €0.34 EUR +0.001
Swedish Orphan Biovitrum AB kr119.50 SEK 0.00
Veloxis Pharmaceuticals A/S kr1.08 DKK 0.00
View Industry Companies
 

Industry Analysis

OXB

Industry Average

Valuation OXB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.3x
Price/Book 10.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXFORD BIOMEDICA PLC, please visit www.oxfordbiomedica.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.